Product Information
BUPROPION HCL XL 150 MG TABLET is a generic product labeled by Granules Pharmaceuticals Inc., priced at $0.0785 per EA under NDC 70010078403. Its NADAC has been published 108 times since Sep 11, 2024.
FDA first approved this application on Feb 2, 2022. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Granules Pharmaceuticals Inc.NDC
70010078403
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUPROPION HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215568FDA Approved
2/2/2022
TE Code
AB3
On Market Since
12/15/2022
Pharmacological Classes
Price Statistics
The NADAC for BUPROPION HCL XL 150 MG TABLET has been published 108 times since Sep 11, 2024, and over the history we have for it it has declined 27.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0785 per EA |
|---|---|
| All-time high | $0.1098 (Oct 16, 2024) |
| All-time low | $0.0745 (Nov 20, 2024) |
| 52-week high | $0.0996 |
| 52-week low | $0.0770 |
| Median price | $0.0899 |
| Average price | $0.0918 |
| Largest weekly change | -30.3% (Nov 20, 2024) |
| Weeks tracked | 108 |
| Tracking since | Sep 11, 2024 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Granules Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bupropion hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoketone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPROPION HCL XL 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPROPION HCL XL 150 MG TABLET, manufactured by Granules Pharmaceuticals Inc., is $0.0785 per EA (NDC 70010078403), effective Sep 30, 2026.
How has the price of BUPROPION HCL XL 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUPROPION HCL XL 150 MG TABLET has declined 27.1%. It has been tracked across 108 weekly CMS publications since Sep 11, 2024.
What are the highest and lowest recorded NADAC prices for BUPROPION HCL XL 150 MG TABLET?
Since Sep 11, 2024, the NADAC for BUPROPION HCL XL 150 MG TABLET has ranged from a low of $0.0745 (Nov 20, 2024) to a high of $0.1098 (Oct 16, 2024), with a median of $0.0899 per EA.
Are there cheaper alternatives to BUPROPION HCL XL 150 MG TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUPROPION HCL XL 150 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPROPION HCL XL 150 MG TABLET?
BUPROPION HCL XL 150 MG TABLET (NDC 70010078403) is labeled by Granules Pharmaceuticals Inc., and CMS classifies it as a generic product.